AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05255107 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution
Description: Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the experimental arm, riboflavin will be administered (1 drop every 2 min for 40 min with PESCHKE-L solution \[0.23%\], or longer as needed to assure adequate corneal penetration). Then the eye will be aligned under the PXL Platinum 330 light (the treatment plane will be at the correct working distance from the PXL Platinum 330 beam aperture when the border of the projected beam is in sharp focus). The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).
Study NCT05255107 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care Therapy + Sham CXL + Artificial Tears
Description: Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the Sham comparator group, artificial tears (1 drop every 2 min for 40 min) will be administered. After instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min, during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
Study NCT00988182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein
Study NCT00988182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water control
Study NCT04832035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coordinated and peer supported mental health care
Description: Health services, coordination of services, method to support utilization
Study NCT04832035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard psychotherapeutic care in the public healthcare system
Description: Psychotherapeutic services that are financed by the public health insurance system.
Study NCT04832035 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard psychotherapeutic care in the public healthcare system
Description: Psychotherapeutic services that are financed by the public health insurance system.
Study NCT05813561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40mg
Study NCT05813561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012
Description: DWP14012 40mg
Study NCT06466200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Schiff Test
Description: Use of an air syringe positioned perpendicular to the tooth surface at a distance of 1 cm. A scale to determine the intensity of DH was created, with the SASS (Shiff Analog Sensitivity Scale) ranging from 0 to 3 (0 being the absence of pain felt by the patient and 3 being pain considered intolerable). If the pain is greater than 1 then the patient is considered hypersensitive.
Study NCT06466200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GOHAI questionnaire
Description: Oral health-related quality of life assessment by questionnaire
Study NCT06466200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OHIP questionnaire
Description: Oral health-related quality of life assessment by questionnaire
Study NCT06466200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DHEQ fr questionnaire
Description: dentin hypersensitivity and oral health-related quality of life assessment by questionnaire
Study NCT04630353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201 IV
Description: HB-201 given IV, one (1) time, on day 1.
Study NCT04630353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201 IV
Description: HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
Study NCT05803707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Adapted Physical Activity
Description: There will be 8 weekly sessions at a time defined in advance for the same group and for the 8 sessions
Study NCT05490082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron, Propevirine, Solifenacin
Description: Efficacy comparison
Study NCT05490082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirabegron, Propevirine, Solifenacin
Description: Efficacy comparison
Study NCT06003764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: low-frequency PEMFT (15 Hz, 50% intensity output for 5 s/min for 20 minutes)
Study NCT06003764 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional skin care
Description: traditional skin care( the patients received the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing was used. Additionally, the patient was advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing
Study NCT06003764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional skin care
Description: traditional skin care( the patients received the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing was used. Additionally, the patient was advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing
Study NCT05043935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF with antimicrobial photodynamic therapy
Description: Application of L-PRF with antimicrobial photodynamic therapy in the defect
Study NCT05043935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial photodynamic therapy without L-PRF
Description: application of antimicrobial photodynamic therapy without L-PRF in the defect
Study NCT04909762 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Rehabilitation and Mobilisation (ERM)
Description: Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package. It is provided by health professionals from multiple disciplines and care-givers within intensive care settings.
Study NCT04993846 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dental plaque sampling
Description: Dental plaque sampling
Study NCT04993846 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: qPCR
Description: qPCR
Study NCT05617365 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy and Exercise Therapy
Description: At the physician's discretion, each subject will receive a minimum of 4 treatments up to a maximum of 8 treatments over the 12-week duration of the study (Haas et. al., 2018). The patients may be treated in the seated, prone and/or supine positions. Duration of treatment will depend on the degree of documented dysfunction but will be limited to one half hour. The techniques utilized by the physician may vary for many reasons including the degree of restriction, acuity, or patient cooperation.~The THE protocol will involve subjects performing cyclic voluntary retraction and protrusion of their head.
Study NCT05498727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics
Description: This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.
Study NCT04704050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dronedarone 400 mg Oral Tablet
Description: Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV.~Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks.
Study NCT04704050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
Study NCT00733798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-TM601
Description: After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
Study NCT05115929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive Laparotomy
Description: As described in the study protocol a long midline laparotomy is performed and open abdomen therapy using negative pressure dressings initiated to lower abdominal pressure and thereby improve venous return from the brain to lower intracranial pressure.
Study NCT05115929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive Craniectomy
Description: As described in the study protocol a sufficiently sized hemi-craniectomy is performed and the skin closed over the bony defect to allow cerebral swelling and thereby lower intracranial pressure.
Study NCT05033041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study drug metoclopramide
Description: Intravenous administration of 4 mg metoclopramide
Study NCT05033041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Study drug placebo administration
Description: Intravenous administration of placebo (sterile normal saline)
Study NCT05244096 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study
Study NCT05955066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG
Description: 1 capsule (4mg) daily for 24 weeks
Study NCT05955066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily
Study NCT06516120 — intervention group
Intervention type: BEHAVIORAL
Intervention: RGS-app
Description: Participants use the RGS-app on a smartwatch once for 1.5 hours during the measurement. The RGS-app consists of augmented reality games to provoke upper limb movement.
Study NCT04749199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced mirror therapy
Description: Participants of the enhanced mirror therapy group will perform complex, randomized, finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a 35% blurred visual feedback through the computerized mirror therapy device. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
Study NCT04749199 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Standard mirror therapy
Description: Participants allocated to this group will perform simple, sequential finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a clear image of the exercising hand. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
Study NCT04761250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
Study NCT06478914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: NMES unit manufactured by Enraf-Holland was be used to administer the neuromuscular electrical stimulation (NMES) The study involved adjusting the patient's hips, knees, and ankles to achieve a comfortable position. Two electrodes of NMES were used in the first study group and a placebo in the control group. The electrodes were placed on the popliteal fossa and fibular head, and each session was conducted for 15 minutes daily for 2 months.
Study NCT06478914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity laser therapy (LILT)
Description: The laser unit is a small, hand-held, class III laser product manufactured by Laserex Technology Pty Ltd Australia. It offers continuous and pulsed laser therapy, with continuous therapy being the most effective. The device has a maximum average power of 5 milliwatts, a wavelength of 820 nm, and a power density of 0.39 W/cm2.~Patients were treated as outpatients, receiving full explanations about the purpose, therapeutic, and physiological benefits of low-intensity laser therapy (LILT). They were relaxed in supine position, with hips and knees adjusted. The patient was irradiated in a continuous mode and direct contact method, 3 times per week for 2 months, at 1-cm intervals and across the surface in grids. The laser applicator was applied to the surface, maintaining contact for maximum penetration.
Study NCT06403943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BaiDiZiYin Pill, ShenQiYiFei Pill
Description: Indications of BaidiZiyin Pill: Nourishing the lungs and kidneys, cooling blood and removing steam. Used as an adjunctive treatment for tuberculosis caused by lung and kidney deficiency and qi yin injury, including coughing, shortness of breath, dry cough with less phlegm, hot flashes and night sweats, cold and spontaneous sweating, hoarseness, palpitations, cold limbs, and emaciation.~Indications of ShenqiYifei Pill: expectorant and cough relieving. It is suitable for patients with pulmonary tuberculosis and spleen diseases, as well as phlegm dampness retention. Symptoms include short breath, low sound, clear and thin phlegm, limited appetite, bloating and loose stools, pale complexion, fatigue and chest tightness, emaciation, and fear of cold and spontaneous sweating.
Study NCT06403943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti tuberculosis chemotherapy
Description: 2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
Study NCT06403943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti tuberculosis chemotherapy
Description: 2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
Study NCT06433648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ottobock CLeg4 + Ottobock foot
Description: Commercially available Ottobock CLeg 4 microprocessor knee unit and Ottobock foot.
Study NCT06433648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ottobock CLeg4 + Ottobock foot
Description: Commercially available Ottobock CLeg 4 microprocessor knee unit and Ottobock foot.
Study NCT06433648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SRALAB Hybrid Knee + Polycentric Ankle
Description: Experimental powered prosthesis: SRALAB Hybrid Knee and powered polycentric ankle.
Study NCT06433648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRALAB Hybrid Knee + Polycentric Ankle
Description: Experimental powered prosthesis: SRALAB Hybrid Knee and powered polycentric ankle.
Study NCT06433648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRALAB Hybrid Knee + Passive Ankle
Description: Experimental powered prosthesis: SRALAB Hybrid Knee and passive ankle.
Study NCT06433648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ottobock CLeg 4 + Polycentric Ankle
Description: Commercially available Ottobock CLeg 4 prosthetic knee and SRALAB powered polycentric ankle.
Study NCT05232721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The new instrument and colonoscopy with pathological examination
Description: Detect hemoglobin in stool by the point-of-care testing instrument before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
Study NCT06525168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA414 Granules
Description: DA414 Granules single ascending doses. DA414 will be orally administrated at single ascending doses of 12.5 mg, 25mg, 50 mg, 100mg and 200 mg.
Study NCT06525168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA414 placebo
Description: DA414 placebo single ascending doses. DA414 placebowill be orally administrated at single ascending doses of 25mg, 50 mg, 100mg and 200 mg.
Study NCT04479072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Study NCT04479072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Study NCT05833815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg
Description: Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx
Study NCT05833815 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care
Description: GemOx or CapOx
Study NCT06433284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade
Description: Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole
Study NCT06433284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade
Description: Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining then filling the hole with amniotic membrane hydrogel and sulfur hexafluoride (SF6) tamponade
Study NCT05368649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy
Description: The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
Study NCT04938336 — intervention group
Intervention type: BEHAVIORAL
Intervention: Delphi Procedure and interviews
Description: Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers
Study NCT05759793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T (CAR-GPRC5D)
Description: CAR-GPRC5D is an individualized, gene-modified autologous T cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. CAR specifically recognizes GPRC5D with a hypoimmunogenic human single-chain variable fragment (ScFv) that promotes car-T activation, proliferation and cytokine secretion. The persistence of CAR-T is enhanced by 4-1BB costimulation signal.
Study NCT06532305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE empowerment classes
Description: A three-month empowerment course.
Study NCT06532305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HOPE empowerment classes
Description: A three-month empowerment course.
Study NCT05363774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.
Study NCT05363774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0519-0130)
Description: SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels.